Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 91, Issue 1, Pages 47-50Publisher
SPRINGER
DOI: 10.1007/s11060-008-9676-4
Keywords
Advanced renal cell carcinoma; Sorafenib; Brain metastases
Categories
Ask authors/readers for more resources
We report the case of a 75-year old woman who received sorafenib (Nexavar (R), Bayer Pharmaceuticals Corporation, West Haven, CT) for a CNS relapse of clear cell renal cell carcinoma. After four months of sorafenib treatment, a brain magnetic resonance imaging showed 95%-volumetric regression of cerebral metastasis. To the best of our knowledge, this is the first almost complete resolution of brain metastases in renal cell carcinoma treated with sorafenib that has been described.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available